Partnerships

Partnership With Janssen

Janssen Biotech Logo

Janssen Biotech, Inc.

We have a license agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for our bacterial consortia drug candidate for Inflammatory Bowel Diseases VE202.

Partnership With Bristol Myers Squibb, Inc.

Bristol-Myers Squibb

Bristol Myers Squibb, Inc.

We have a clinical trial collaboration agreement with Bristol Myers Squibb for our bacterial consortia drug candidate for Immune-Oncology VE800.

Partnership with CARB-X

 Partnership with CARB-X

Vedanta has been awarded two research grants from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) to support the development of VE303, the Company’s product candidate for the treatment of high-risk C. difficile infection (CDI) and VE707, Vedanta’s preclinical discovery program for the prevention of infection and recurrence of several MDROs, including carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta lactamase producers (ESBL), and vancomycin-resistant Enterococci (VRE).

Partnership with JSR Corporation

Partnership with JSR Corporation

JSR Corporation

We have a collaboration agreement with JSR to develop next-generation manufacturing techniques for live biotherapeutic products.

Academic Collaborations

Academic Collaborations

NYU Langone Medical Center

We have entered into a translational collaboration with the NYU Langone Medical Center focused on developing novel microbiome-derived immunotherapies for cancer patients being treated with checkpoint inhibitors.

Leiden University Medical Center

We have entered into a clinical translational medicine collaboration with Leiden University Medical Center that focuses on collection of samples from healthy donors as well as clinical data and/or interventional studies of fecal transplantation in a variety of indications.

Centre hospitalier de l'Université de Montréal

We have entered into a translational collaboration with CHUM focused on understanding the microbiome of cancer patients being treated with checkpoint inhibitors.

Hôpital Raymond Poincaré

We have entered into a translational collaboration with Hôpital Raymond Poincaré focused on the development of microbiome-based therapeutics for multi-drug resistant organisms.

The Leading Platform for Development of Bacterial Consortia Therapeutics

Our discovery platform enables identification of bacterial consortia with drug-like properties and their manufacture to GMP standards.

How Our Proprietary Discovery Platform Works